KRTX(Delisted)
Karuna TherapeuticsยทNASDAQ
--
--(--)
KRTX Profile
Karuna Therapeutics, Inc.
A clinical-stage biopharmaceutical company that develops therapies to address disabling neuropsychiatric conitions
99 High Street, 26th Floor, Boston, Massachusetts, 02110
--
Karuna Therapeutics, Inc., was incorporated in July 2009 under the laws of the State of Delaware. They are an innovative clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric disorders characterized by serious unmet medical needs. Their product line builds on the broad therapeutic potential of their lead drug candidate, KarXT, an oral modulator of muscarinic receptors located in the central or central nervous system and various peripheral tissues. KarXT is their patented product candidate, which binds the novel muscarinic agonist xanomeline to the approved muscarinic antagonist trospium, preferentially stimulating muscarinic receptors in the central nervous system. They are currently conducting a Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia and expect final results by the end of 2019.
